Lakefront Biotherapeutics American Depositary Shares
LKFT
90 hedge funds and large institutions have $938M invested in Lakefront Biotherapeutics American Depositary Shares in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 13 closing their positions.
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
18% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 28
0% more funds holding
Funds holding: 90 → 90 (0)
0.2% less ownership
Funds ownership: 47.64% → 47.44% (-0.2%)
9% less capital invested
Capital invested by funds: $1.03B → $938M (-$92.8M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
98% less call options, than puts
Call options by funds: $303K | Put options by funds: $16.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$15.8M |
| 2 |
MAP
Madison Avenue Partners
New York
|
+$8.34M |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$3.17M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.19M |
| 5 |
HF
HRT Financial
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.66M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.77M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.48M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3.06M |
LKFT Hedge Fund Activity: Q1 2026 in Review
90 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2026, worth a combined $938M — down 9% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LKFT positions and 13 closed out — a net gain of 3 holders — while 33 added to existing stakes and 28 trimmed.
The largest buyer was Prosight Management, adding an estimated $15.8M. The largest seller was Millennium Management, cutting an estimated $7.66M.
- 90 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $938M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2026, down 9% quarter-over-quarter.
- 16 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2026 and 13 closed out, a net change of +3 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2026 was Prosight Management, an estimated $15.8M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2026 was Millennium Management, an estimated $7.66M sold.
Based on aggregated 13F filings for Q1 2026.